Q-omics provides the consensus-scored HCN4 profile across patient tissues and cancer cell-line models. HCN4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HCN4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, HCN4 protein abundance shows 21,772 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where HCN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCN4 survival associations across molecular data types. HCN4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCN4 RNA expression–survival associations across cancer types. High HCN4 expression shows unfavorable associations in KIRC, KIRP, MESO, STAD and CHOL, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HCN4 RNA expression.
This table summarizes HCN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HCN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCN4 shows lower tumor expression in COAD, KICH, KIRC and LUSC and higher tumor expression in THCA and BRCA. The THCA box plot shows higher HCN4 RNA expression in tumor versus normal tissue (log2 FC = +2.029, t-test p < 0.001).
This table shows molecular features associated with HCN4 in patient tissues and cancer cell lines. In patient samples, HCN4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HCN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
